Companies › Eidos Therapeutics, a BridgeBio company
1 active drug program in 4 registered trials: 2 Phase 3, 1 Phase 4, 1 Phase 2; Neurology, Cardiovascular; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Acoramidis Transthyretin stabiliser | TTR | Phase 4 | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloid Cardiomyopathy, Transthyretin-Related; Amyloidosis; Amyloid Cardiomyopathy | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03536767 | Acoramidis | Phase 2 | Amyloid Cardiomyopathy | Neurology | Sep 2025 |
| NCT04988386 | Acoramidis | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related | Cardiovascular | Apr 2028 |
| NCT07695701 | Acoramidis | Phase 4 | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Neurology | Aug 2030 |
| NCT06563895 | Acoramidis | Phase 3 | Amyloidosis | Neurology | Oct 2031 |
Cash and short-term investments of $1.5bn on 2026-09-30; operating cash outflow about $419m a year; runway about 44 months at that burn, to May 2030; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Alnylam Pharmaceuticals AstraZeneca Novo Nordisk Neurimmune Intellia Therapeutics Ionis Pharmaceuticals Qilu Pharmaceutical
Neurimmune Inhibikase Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou) Shenzhen Ausa Pharmed Lantheus Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.